5-methanesulfonyl-1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine | 400798-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methanesulfonyl-1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
• 英文别名: 5-methylsulfonyl-1-(oxiran-2-ylmethyl)-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine
• CAS: 400798-00-7
• 化学式: C₁₇H₁₈F₃N₃O₃S
• 分子量: 401.409
• InChiKey: MFICZYBNZJIOPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  76.1
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  5-methanesulfonyl-1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine 、 3-(4-哌啶基)-1H-吡咯并[2,3-b]吡啶 以 乙醇 为溶剂， 生成 1-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-piperidine-1-yl]-propan-2-ol
  参考文献：
  名称：

  Pyrazole-based cathepsin S inhibitors with improved cellular potency

  摘要：

  High potency pyrazole-based noncovalent inhibitors of human cathepsin S (CatS) were developed by modification of the benzo-fused 5-membered ring heterocycles found in earlier series of Cats inhibitors. Although substitutions on this heterocyclic framework had a moderate impact on enzymatic potency, dramatic effects on cellular activity were observed. Optimization afforded indole- and benzothiophene-derived analogues that were high affinity Cats inhibitors (IC50 = 20-40 nM) with good cellular potency (IC50 = 30-340 nM). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.038
• 作为产物：
  描述：

  5-(methylsulfonyl)-3-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine 、 环氧氯丙烷 在 caesium carbonate 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 以4.1g (35%)的产率得到5-methanesulfonyl-1-oxiranylmethyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
  参考文献：
  名称：

  Method for treating allergies using substituted pyrazoles

  摘要：

  使用取代吡唑醇治疗过敏症状的方法，包括特应性过敏症状。

  公开号：

  US20030073672A1

文献信息

• [EN] PROCESS FOR THE PREPARATION OF CATHEPSIN S INHIBITORS<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'INHIBITEURS DE LA CATHEPSINE S
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011019842A1

  公开（公告）日：2011-02-17

  Inhibitors of Cathepsin S enzyme and their synthetic processes.

  Cathepsin S酶抑制剂及其合成过程。
• Substituted pyrazoles
  申请人：Butler R. Christopher

  公开号：US20050245576A1

  公开（公告）日：2005-11-03

  Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.

  本文描述了替代吡唑的制备方法、含有它们的组合物以及使用它们治疗由cathepsin S介导的自身免疫性疾病的方法。
• Substituted pyrazoles and methods of treatment with substituted pyrazoles
  申请人：Butler R. Christopher

  公开号：US20070117785A1

  公开（公告）日：2007-05-24

  Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases or allergic conditions, including atopic allergic conditions, mediated by cathepsin S are described.

  本文描述了替代吡唑的制造方法、含有它们的组合物以及使用它们治疗自身免疫性疾病或过敏症的方法，包括由cathepsin S介导的过敏症，例如特应性过敏症。
• PROCESS FOR THE PREPARATION OF CATHEPSIN S INHIBITORS
  申请人：Liang Jimmy T.

  公开号：US20120142928A1

  公开（公告）日：2012-06-07

  Inhibitors of Cathepsin S enzyme and their synthetic processes.

  Cathepsin S酶抑制剂及其合成过程。
• Process for the preparation of cathepsin S inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US20140179924A1

  公开（公告）日：2014-06-26

  Inhibitors of Cathepsin S enzyme and their synthetic processes.

  Cathepsin S酶抑制剂及其合成过程。